(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 6.88% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.34%.
Abbvie's revenue in 2025 is $59,644,000,000.On average, 31 Wall Street analysts forecast ABBV's revenue for 2025 to be $109,523,058,260,408, with the lowest ABBV revenue forecast at $104,411,781,904,664, and the highest ABBV revenue forecast at $113,644,599,222,232. On average, 31 Wall Street analysts forecast ABBV's revenue for 2026 to be $119,567,105,124,064, with the lowest ABBV revenue forecast at $111,854,238,590,016, and the highest ABBV revenue forecast at $127,435,501,505,728.
In 2027, ABBV is forecast to generate $128,497,699,669,560 in revenue, with the lowest revenue forecast at $119,372,692,814,544 and the highest revenue forecast at $139,254,002,539,912.